This is consistent with other studies using BTZ to increase the gross cellular function of proteins mutated in a range of conditions, including RP, Niemann–Pick disease type C, mitochondrial leukoencephalopathy, and Lynch syndrome (Macías-Vidal et al., 2014; Zhang et al., 2019). This evidence concerns the gene CASC3 and Lynch syndrome.